The FDA's approval of a new generic version of mifepristone has sparked backlash from anti-abortion groups and GOP politicians. Critics say it's a political move during a heated debate over abortion rights.
In a surprising turn, the Trump administration has requested a federal judge to dismiss a lawsuit aimed at restricting access to the abortion pill mifepristone, aligning with the Biden administration's stance. This case holds significant implications for abortion rights and reproductive health access.
In a tense Senate confirmation hearing, Dr. Marty Makary outlined his ambitious plans for the FDA, including a comprehensive review of school lunches and the abortion pill mifepristone. Will he transform American health policies?
